Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular
suspension) 9%.

DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

Cataract

This retrospective study is intended to provide large-scale, real-world data on clinical
outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.

DEXYCU (dexamethasone intraocular suspension) 9%.

Of eyes with a record at postoperative day 8, percentage with anterior chamber cell grade
0. Cells in the anterior chamber of the eye are indicative of intraocular inflammation
and are evaluated using a slit-lamp biomicroscope; a grade of 0 indicates that no
inflammatory cells were visible in a 1 mm by 1 mm slit beam.

DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the
posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9%
(equivalent to 517 micrograms).

Eye Center South Locations

Inland Eye Specialists

Harvard Eye Associates

Coastal Vision Medical Group

North Bay Eye Associates, Inc.

The Eye Associates of Manatee, LLP

Eye Physicians of Pinellas, PA, dba The Eye Institute of West Florida

Jacksoneye, SC

Hauser-Ross Eye Institute

Price Vision Group

Physicians Eyecare Center

Discover Vision Centers

Silverstein Eye Centers

Tekwani Vision Center

Surgery Center of Central New Jersey

New York Eye Surgery Center

SightMD, PLLC

Island Eye Surgicenter

Wills Surgery Center

VRF Eye Specialty Group

Valley Retina Institute, PA

The Eye Centers of Racine and Kenosha

DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

About this trial

Study ID

Status

Type

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?

Locations

Location

Status